科研之友
微信
新浪微博
Facebook
分享链接
摘要
The impact of radioiodine-131 (I-131) treatment on thyroid cancer patients' quality of life is controversial. We conducted a cross-sectional study of 60 patients aged 18-73 years old who had recently underwent near total thyroidectomy due to papillary thyroid cancer and were scheduled for I-131 treatment. On admission to our department, prior to I-131 administration patients underwent clinical and laboratory investigation including routine clinical biochemistry, thyroid stimulating hormone (TSH) and thyroglobulin (Tg) measurements. Health-related quality of life (HRQoL) was estimated by the SF- 36 Health Survey a generic instrument which consisted from eight scales (four for physical and four for mental health). After I-131 administration patients were discharged and approximately 6 months later they were re-evaluated. Our results showed that HRQoL in thyroid cancer patients receiving I-131 treatment is independent of age/gender and thyroid cancer-related variables. All SF-36 scales significantly improved six months after administration (P<0.05). Compared to Greek general population, before I-131 administration all scales were significantly lower (P<0.05). Six months post I-131 administration, scales were significantly lower for physical functioning (P=0.02), physical role (P=0.01), social functioning (P=0.03) and emotional role limitations (P=0.04), whereas the remaining SF-36 scales were comparable to the general population. In conclusion, hypothyroidism and anxiety for the outcome of their disease before I-131 treatment exert a negative impact on thyroid cancer patients. Quality of life improvement post I-131 is mainly attributed to the resumption of euthyroidism and familiarization with treatment and follow-up procedures rather than I-131 treatment itself. There was no significant difference between patients receiving lower (2220-3700MBq) and higher (3700-7400MBq) dosage.
- 出版日期2012-8
